Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Thursday, November 10 • 10:30 - 12:00
Unleashing Innovations in Personalized Healthcare / Libérer les innovations en matière de soins de santé personnalisés

Sign up or log in to save this to your schedule and see who's attending!

Organized by, Hoffmann-La Roche Ltd., Dana Corsen 

The field of personalized healthcare is broad and diverse, ranging from individualized care within the family practice, to the possibilities unleashed by advancements in genomic sequencing.   It is well known that the rate of scientific research and discovery has outpaced system capacity and infrastructure in Canada.   Governments, institutions, and healthcare practitioners across Canada are grappling how to effectively accommodate the adoption of the latest diagnostic and therapeutic tools.   This panel will focus on innovations in personalized healthcare- particularly as it relates to cancer - and the policy issues that must be addressed in Canada in order to facilitate the integration of new scientific tools and discoveries.

In particular, the panel will address how innovations in sequencing technologies and the use of real world evidence have changed the face of cancer treatment and research.   Molecular information promises to play a pivotal role in the development of novel treatment options for patients to advance personalized healthcare, but is the policy infrastructure in place in Canada to facilitate the uptake of such innovations? 

The objective of this panel will be to examine key policy considerations related to:

• Real world evidence – How does the Canadian system currently utilize it? How could advancements in collaborative, coordinated data collection and integration optimize research and patient care in Canada?

• How the advent of tumor sequencing can challenge the standard of care and the long term insights that can fuel research for break through treatments in cancer

• Examine how real-world evidence and outcomes derived from patient data captured outside of clinical trials can empower informed decision making by:

          - providing insights into the safety and efficacy of new therapies

          - driving greater effectiveness and efficiency in research

          - supporting evidenced-based decisions on access to medicines

• Discuss why and how industry can play a supportive role to help achieve common objectives

Moderators
avatar for Peter Goodhand

Peter Goodhand

Executive Director, Global Alliance for Genomics and Health
Peter Goodhand is a leader in the global health sector as a senior executive and board member.In May 2016, he was appointed Interim President of the Ontario Institute for Cancer Research (OICR) ‎in addition to his role as the Executive Director of the Global Alliance for Genomics and Health (GA4GH). Goodhand played a key role in the creation of the GA4GH and was appointed as its founding Executive Director in 2014. Prior to this role, he... Read More →

Speakers
avatar for Louise Binder

Louise Binder

Health Policy Consultant, Canadian Cancer Survivor Network
Louise Binder is a lawyer who has been involved in informing the development of health policy and systemic treatment access practices from a patient perspective for more than 20 years. She started her work in this area in the HIV community in the early 1990s after her own diagnosis and before effective treatments were available for HIV. She cofounded the Canadian Treatment Action Council (CTAC) in 1996 that successfully ensured access... Read More →
avatar for Bill Capra

Bill Capra

Senior Director and Global Head of Oncology for the Real World Data Science function, Roche/Genentech
One of his passions is finding innovative uses for RWD in drug development.  Bill leads a group of over 20 RWD Scientists located in Switzerland, the UK, and USA. As a trained biostatistician, Bill has over 20 years experience in all phases of clinical trials, with a focus primarily on oncology and infectious diseases. At Roche /Genentech Bill frequently serves on review and oversight committees, advising and guiding molecule development... Read More →
avatar for Susan Hagar

Susan Hagar

Senior Vice President, Corporate Communications and Government Affairs, Foundation Medicine
Ms. Hager joined Foundation Medicine in December 2014, bringing more than 15 years of strategic marketing, corporate and financial communications expertise in the life sciences industry to her role at Foundation Medicine. Her experience includes strategic communications in support of corporate and product brands, strategic financings and acquisitions, and regulatory actions. Prior to joining Foundation Medicine, Ms. Hager previously served as... Read More →
avatar for Étienne Richer

Étienne Richer

Associate Director, Institute of Genetics of the Canadian Institutes of Health Research (CIHR)
Dr. Étienne Richer first joined McGill University as a postdoctoral scientist in genetics of infectious diseases. Dr. Richer then joined BioMedCom Consultants where he was involved in projects covering a broad range of healthcare issues from biologics therapies to reimbursement policies. Dr. Richer returned to McGill in 2011 as the Associate Director for the CIHR Institute of Genetics. Dr. Richer has been involved in the strategic... Read More →


Thursday November 10, 2016 10:30 - 12:00
Room 211

Attendees (12)